ClinicalTrials.gg
RecruitingNCT06831123Updated Apr 13, 2026

Pathways 2 Success

A Phase 1/2 interventional study of L2B and L2B + App in Conduct Disorder and Oppositional Defiant Disorder, sponsored by University of Minnesota. Recruiting at 1 site in United States. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by University of Minnesota · Phase 1/2, Interventional, and Prevention

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.
Phase
Phase 1/2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
13 Years to 17 Years
Sex
All
01

Study summary

This study involves a 3-arm randomized controlled trial designed to investigate the feasibility and acceptability of three preventive interventions designed to reduce risk for escalations in adolescent conduct problems. High school students identified to be at risk for conduct problems will be randomly assigned to one of three intervention options, including a mindfulness-based program, a mindfulness-based program augmented by a new mobile app, and a life skills program. Assessments related to intervention outcomes will be completed by adolescents, parents/guardians, and teachers at baseline, 2 weeks post-intervention, and at a 3-month follow-up.

02

Conditions studied

  • Conduct Disorder
  • Oppositional Defiant Disorder
03

In context

Conduct Disorder

101 studies on the registry are indexed under Conduct Disorder; 15 are open to participants now.

This study's planned enrollment of 120 is close to the median of 124 across 80 interventional studies indexed under Conduct Disorder.

Browse Conduct Disorder studies →

Lead sponsor

University of Minnesota is the lead sponsor of 1,216 studies on the registry; 197 are open to participants now.

Of its 136 completed or terminated interventional studies of FDA-regulated products, 95 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
13 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A 9th or 10th grade student in a partner school district
  2. Referral due to elevated social/emotional risk indicated on a standardized screening tool or a referral from school support staff due to concerns about school-based conduct problems
  3. Adolescents and their parents must be fluent in English

Exclusion criteria

Exclusion Criteria:

  1. Currently receiving special education services (i.e., an IEP) due to a behavioral or emotional disturbance
  2. Existing diagnoses of autism spectrum disorder, pervasive developmental disorders, developmental/intellectual disability, or serious psychiatric disorders requiring specialized mental health treatment (e.g., psychosis, bipolar, substance use disorder, etc.)
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    The Learning to breathe (L2B)

    randomized to the Learning to Breathe (L2B) mindfulness intervention

    Behavioral: L2B

  • Experimental
    L2B+App

    randomized to the Learning to Breathe plus App condition

    Behavioral: L2B + App

  • Experimental
    Skills for Success

    randomized to Skills for Success

    Behavioral: skills for success

Interventions

  • BehavioralL2B

    a 6-session, group-based intervention that helps youth develop mindfulness skills

  • BehavioralL2B + App

    the Learning to Breathe plus App condition, the 6-session L2B intervention augmented by a mobile application designed to support the use of mindfulness skills in daily life

  • Behavioralskills for success

    a 6-session life skills intervention designed to support decision making and healthy relationships

06

What researchers measure

Primary outcomes

  1. Add Health Self-Report of Delinquency

    A rating scale used to evaluate the number of times in the past month adolescents have committed 17 different antisocial acts. A rating scale used to evaluate the number of times in the past month adolescents have committed 17 different antisocial acts. Scores range from 0 to 17, with higher scores reflecting greater engagement in delinquent behaviors.

    Time frame: Baseline; up to 15 weeks; through study completion, approximately 6 months

  2. Behavioral Rating Inventory of Executive Functioning - Second Edition Screening Form

    A 12-item rating scale that evaluates executive functioning A 12-item rating scale that evaluates executive functioning. Scores are reported as T-scores, with higher scores reflecting greater levels of executive functioning difficulties.

    Time frame: Baseline; up to 15 weeks; through study completion, approximately 6 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Feb 2027, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2025
First posted
Feb 17, 2025
StartActual
Mar 12, 2025
Primary completionEst.
Feb 28, 2027
CompletionEst.
Feb 28, 2027
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06831123
Responsible party
Sponsor
First posted
Feb 17, 2025
Start date
Mar 12, 2025
Primary completion
Feb 28, 2027 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Apr 13, 2026

Study contacts

Nicole Morrell
Contact
morre006@umn.edu
612-624-2600
Timothy Piehler
principal investigator · University of Minnesota

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion